Terminated PHASE2 INTERVENTIONAL 2-arm NCT00850499

Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

A Randomized, Open-Label, Multicenter Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions Follicular Lymphoma

Interventions VELCADE fludarabine rituximab

Updated 8 times since 2017 Last updated: Dec 10, 2012 Started: Sep 30, 2009 Primary completion: Sep 30, 2011 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

More terminations from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Other Follicular Lymphoma trials with similar outcome

Browse all Follicular Lymphoma trials

Listed as NCT00850499, this PHASE2 trial focuses on Follicular Lymphoma and remains terminated or withdrawn. Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., it has been updated 8 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Millennium Pharmaceuticals, Inc.

Data source: Millennium Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Afula, Israel , Amiens, France , Athens, Greece , Bamberg, Germany , Bari, Italy , Berlin, Germany , Berlin, BE, Germany , Bologna, Italy , Bordeaux, France , Cadiz, Spain and 32 more locations